

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM708787

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	INTELLECTUAL PROPERTY SECURITY AGREEMENT		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
EMME, INC.		02/16/2022	Corporation: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	JPMORGAN CHASE BANK, N.A.		
<b>Street Address:</b>	383 Madison Avenue, 22nd Floor		
<b>City:</b>	New York		
<b>State/Country:</b>	NEW YORK		
<b>Postal Code:</b>	10179		
<b>Entity Type:</b>	National Banking Association: UNITED STATES		
<b>PROPERTY NUMBERS Total: 1</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	6434975	EMME	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	800-494-5225		
<b>Email:</b>	ipteam@cogencyglobal.com		
<b>Correspondent Name:</b>	Stewart Walsh		
<b>Address Line 1:</b>	1025 Connecticut Ave NW, Suite 712		
<b>Address Line 2:</b>	COGENCY GLOBAL Inc.		
<b>Address Line 4:</b>	Washington, D.C. 20036		
<b>ATTORNEY DOCKET NUMBER:</b>	1599780 TM		
<b>NAME OF SUBMITTER:</b>	ANDREW NASH		
<b>SIGNATURE:</b>	/ANDREW NASH/		
<b>DATE SIGNED:</b>	02/16/2022		
<b>Total Attachments: 7</b>			
source=Intellectual Property Security Agreement - Simple Health (Emme)#page1.tif			
source=Intellectual Property Security Agreement - Simple Health (Emme)#page2.tif			
source=Intellectual Property Security Agreement - Simple Health (Emme)#page3.tif			
source=Intellectual Property Security Agreement - Simple Health (Emme)#page4.tif			

OP \$40.00 6434975

source=Intellectual Property Security Agreement - Simple Health (Emme)#page5.tif  
source=Intellectual Property Security Agreement - Simple Health (Emme)#page6.tif  
source=Intellectual Property Security Agreement - Simple Health (Emme)#page7.tif

## INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement (“Agreement”) is entered into as of February 16, 2022, by and between JPMORGAN CHASE BANK, N.A. (“Lender”), as the lender party to the Credit Agreement referred to below, and EMMÉ, INC., a Delaware corporation (“Grantor”).

### RECITALS

A. Lender has made and continue to makes certain advances of money and to extend certain financial accommodation (the “Loans”) to the Loan Parties, in the amounts and manner set forth in that certain Credit and Security Agreement by and among Lender and the Loan Parties dated as of May 19, 2021 (as amended by that certain First Amendment to Credit Agreement, dated as of July 30, 2021, as the same may be further amended, modified or supplemented from time to time, collectively, the “Credit Agreement”; capitalized terms used but not defined herein shall have the meanings assigned in the Credit Agreement). Pursuant to that Joinder Agreement, dated on or about the date hereof (the “Joinder Agreement”), by and between the Lender and the Grantor, the Grantor has agreed, among other things, to become a Loan Party under the Credit Agreement.

B. Pursuant to the terms of the Credit Agreement and the Joinder, Grantor has granted to Lender a security interest in all of Grantor’s right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Credit Agreement, Grantor hereby represents, warrants, covenants and agrees as follows:

### AGREEMENT

1. Grant of Security Interest. Grantor grants and pledges to Lender a security interest in all of Grantor’s right, title and interest in, to and under its intellectual property (all of which shall collectively be called the “Intellectual Property Collateral”), including, without limitation, the following:

(a) Any and all copyright rights, copyright applications, copyright registrations and like protections in each work or authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held, including without limitation those set forth on Exhibit A attached hereto (collectively, the “Copyrights”);

(b) Any and all trade secrets, and any and all intellectual property rights in computer software and computer software products now or hereafter existing, created, acquired or held;

(c) Any and all design rights that may be available to Grantor now or hereafter existing, created, acquired or held;

(d) All patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the same, including without limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the “Patents”);

(e) Any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Grantor

connected with and symbolized by such trademarks, including without limitation those set forth on Exhibit C attached hereto (collectively, the "Trademarks");

(g) Any and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(h) All licenses or other rights to use any of the Copyrights, Patents, or Trademarks, and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(i) All amendments, extensions, renewals and extensions of any of the Copyrights, Trademarks, or Patents; and

(j) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

2. Recordation. The parties hereto authorize and request that the Commissioner of Patents, the Commissioner for Trademarks and the Register of Copyrights of the United States record this security interest in the Intellectual Property Collateral.

3. Authorization. Grantor hereby authorizes Lender to (a) modify this Agreement unilaterally by amending the exhibits to this Agreement to include any Intellectual Property Collateral which Grantor obtains subsequent to the date of this Agreement, and (b) file a duplicate original of this Agreement containing amended exhibits reflecting such new Intellectual Property Collateral.

4. Loan Documents. This Agreement has been entered into pursuant to and in conjunction with the Credit Agreement, which is hereby incorporated by reference. The provisions of the Credit Agreement shall supersede and control over any conflicting or inconsistent provision herein. The rights and remedies of Lender with respect to the Intellectual Property Collateral are as provided by the Credit Agreement and related documents, and nothing in this Agreement shall be deemed to limit such rights and remedies.

5. Execution in Counterparts. This Agreement may be executed in counterparts (and by different parties hereto in different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. Delivery of an executed counterpart of a signature page to this Agreement by facsimile or in electronic (i.e., "pdf" or "tif" format) shall be effective as delivery of a manually executed counterpart of this Agreement.

6. Successors and Assigns. This Agreement will be binding on and shall inure to the benefit of the parties hereto and their respective successors and assigns.

7. Governing Law. This Agreement and any claim, controversy, dispute or cause of action (whether in contract or tort or otherwise) based upon, arising out of or relating to this Agreement and the transactions contemplated hereby and thereby shall be governed by, and construed in accordance with, the laws of the United States and the State of New York, without giving effect to any choice or conflict of law provision or rule (whether of the State of New York or any other jurisdiction).

*[Balance of Page Intentionally Left Blank]*

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

Address:  
Emme, Inc.  
228 Park Ave S., Suite 20627  
New York, NY 10003  
Attention: Carrie Siu Butt

GRANTOR:

EMME, INC.

DocuSigned by:  
By: Carrie Siu Butt  
5D0ACD342B6C435...

Name: Carrie Siu Butt

Title: Chief Executive Officer

Address:  
JPMorgan Chase Bank, N.A.  
383 Madison Avenue, 22th Floor  
New York, NY 10179  
Attention: Grace Mahood

LENDER:

JPMORGAN CHASE BANK, N.A.

By: \_\_\_\_\_

Name: Grace Mahood

Title: Authorized Signatory

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

Address:  
Emme, Inc.  
498 Alabama Street  
San Francisco, CA 94110  
Attention: Carrie Siu Butt

GRANTOR:

EMME, INC.

By: \_\_\_\_\_

Name: \_\_\_\_\_

Title: \_\_\_\_\_

Address:

JPMorgan Chase Bank, N.A.  
383 Madison Avenue, 22th Floor  
New York, NY 10179  
Attention: Grace Mahood

LENDER:

JPMORGAN CHASE BANK, N.A.

By:  \_\_\_\_\_

Name: Grace Mahood

Title: Vice President

EXHIBIT A

Copyrights

<u>Description</u>	<u>Registration/ Application Number</u>	<u>Registration/ Application Date</u>
NONE.		

EXHIBIT B

Patents

<u>Description</u>	<u>Application Number/Registration Number</u>	<u>Application Date</u>	<u>Country</u>	<u>Status</u>
Method and system for improving and assisting in medication compliance	10,925,810	2/23/2021	USA	Registered and Active.
Method and system for improving and assisting in medication compliance	17/157,774	1/25/2021	USA	Published (5/20/2021).
Medication adherence apparatus	29/726,759	3/5/2020	USA	Filed and Allowed.



EXHIBIT C

Trademarks

<u>Description</u>	<u>Registration Number</u>	<u>Registration Date</u>	Country	Status
Emme	6434975	7/27/2021	USA	Registered and Active.